Dernières nouvelles

Information non disponible

Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE

A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

Article de revue

Eur J Haematol, 107 (3), 2021.

Résumé | Liens:

Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE, Hay AE

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.

Article de revue

Am J Hematol, 96 (5), 2021.

Résumé | Liens:

Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, Shepherd LE, Pater JL, Hay AE

Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.

Article de revue

Clin Lymphoma Myeloma Leuk, 20 (11), 2020.

Résumé | Liens:

Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDH

Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.

Article de revue

Leuk Res, 73 , 2018.

Résumé | Liens:

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ, O'Rourke L

Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Article de revue

Haematologica, 103 (12), 2018.

Résumé | Liens:

Laverdiere I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socie G, Levesque E

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Article de revue

Haematologica, 100 (2), 2015.

Résumé | Liens:

Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouelian V, Letarte N, Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lesperance B, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sideris L, Vincent F

Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).

Article de revue

Gynecol Oncol, 131 (1), 2013.

Résumé | Liens:

Bacha OM, Levesque E, Renaud MC, Lalancette M

A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor.

Article de revue

Eur J Gynaecol Oncol, 32 (4), 2011.

Résumé | Liens:

Lalancette M

Protocoles de traitement : service d'hémato-oncologie HDQ-HDL

Livre

Presses de l'Université Laval, Québec, QC, 2010, ISBN: 9782763789569.

Signaler des ajouts ou des modifications